



Financial Tear Sheet

Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed five drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region.

BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of July 2018, the Company had a global team of over 1,300 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization.

Primary IR Contact

Investor Relations
E-mail:
ir@beigene.com

Stock Information

BGNE (American Depositary Shares)

Exchange	NASDAQ GS (US Dollar)
Price	\$124.33

Change (%)	▼ 2.69 (2.12%)
Volume	521,243
52 Week High	\$220.10
52 Week Low	\$77.54
Market Cap	\$98,105,571,632
Rolling EPS	-9.61
PE Ratio	0
Shares Outstanding	772,363,184

Data as of 11/19/18 4:00 p.m. ET

Press Releases

November 16, 2018

[BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology](#)

November 15, 2018

[Priority Review Granted to BeiGene's New Drug Applications for Zanubrutinib and Tislelizumab in China](#)

November 13, 2018

[BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

SEC Filings

Filing Date	Form
11/13/18	4
11/08/18	DEF 14A
11/08/18	10-Q
11/07/18	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed.

Upcoming Events

There are currently no events scheduled.

Corporate Governance

Governance Documents

 [Code of Business Conduct and Ethics](#)


 [Corporate Governance Guidelines](#)

 [Securityholder Communication Policy](#)

Committee Charters

 [Audit Committee](#)

 [Compensation Committee](#)

 [Nominating and Corporate Governance Committee](#)
